explore -WSS

explore

author：fashion 2025-10-01 14:20:10 - browse：4

Pfizer plans to exit a major biotechnology industry trade association. Cindy Ord/Getty Images for Pfizer/BioNTech

WASHINGTON — Pfizer has decided to leave the Biotechnology Innovation Organization, according to two sources familiar with the planning.

The departure is a blow to BIO, which represents members ranging from small biotech startups to massive pharmaceutical companies. The group on Tuesday announced its new CEO, rare disease advocate and biotech executive John Crowley.

“The economic situation for the industry is difficult indeed and we of course are disappointed that any company would be forced to take a break from its BIO membership. We certainly hope that when economic conditions improve, we can welcome those companies back and welcome new members to join us as well, but it in no way affects our mission of protecting patients and medical innovation in the United States,” said BIO’s Chief Public Affairs and Marketing Officer Rich Masters. Masters said he wouldn’t comment on the status of any particular member.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： H5N1 communication has been strictly for the birds

entertainment

WSS

Study fuels hope CAR

Childhood vaccination ad campaign launches in the U.K.

5 ways to address the shortage of health care workers

What nurses really want: sufficient staffing for patient care

Doctor of U.S. President Joe Biden says he is fit for duty

Pfizer is about to make a big push in cancer. Will investors listen?

focus

explore

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

'Vaccine

23andMe had bad news about my health. I wish a person had delivered it

Readout LOUD podcast: brain research, obesity drug sales, Novartis

BioMarin wins approval for gene therapy to treat hemophilia A

Redefining sustainability for the pharmaceutical industry

How to save PrEP access — and even expand it

Childhood vaccination ad campaign launches in the U.K.

BioMarin wins approval for gene therapy to treat hemophilia A

Apple Watch's A

explore

Redefining sustainability for the pharmaceutical industry

STAT Madness 2024: Meet the contenders

Brain worms: The science behind RFK Jr.'s parasitic infection

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Readout Newsletter: Beam, Prozac, "TechBio" and more

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

entertainment

hotspot

entertainment

hotspot